<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2016.54020</article-id><article-id pub-id-type="publisher-id">HJO-19303</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20160400000_29146851.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  微脉冲激光联合与不联合皂苷类药物治疗急性中心性浆液性视网膜脉络膜病变
  Micro-Pulse Laser with or without Aescuvenforte for Treatment of Acute Serous Chorioretinopathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>青山</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>剑虹</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>红婕</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>晓生</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>紫媚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>北京大学深圳医院眼科，广东 深圳</addr-line></aff><aff id="aff2"><addr-line>深圳市眼科医院，深圳市眼科学重点实验室，广东 深圳</addr-line></aff><aff id="aff4"><addr-line>深圳爱尔眼科医院，广东 深圳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>10</month><year>2016</year></pub-date><volume>05</volume><issue>04</issue><fpage>115</fpage><lpage>121</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察微脉冲激光视网膜光凝联合与不联合七叶皂苷素(商品名：迈之灵)治疗急性中心性浆液性视网膜脉络膜病变(Central serous chorioretinopathy, CSC)疗效。方法：临床病例对照研究。选取2014年3月至2015年3月微脉冲激光视网膜光凝治疗的急性CSC患者40例。随机选择单一微脉冲视网膜光凝或与迈之灵联合治疗(以下简称联合治疗)两组，最终完成治疗与随访34例42眼。34例CSC中联合治疗22眼，单一微脉冲激光治疗20眼。比较两组治疗前与治疗后4周，8周最佳矫正视力(BCVA)，FFA及ICGA，黄斑视网膜中心厚度，中心视野的变化。结果：治疗后4周CSC联合治疗组BCVA 0.625 &#177; 0.15，单一治疗组BCVA 0.455 &#177; 0.18 (p = 0.032)，8周联合治疗组BCVA 0.770 &#177; 0.17，单一治疗组BCVA 0.576 &#177; 0.17 (p = 0.027)，两组比较差异均有显著性意义。治疗后4，8周联合治疗组黄斑中心视网膜厚度(CRT)分别为208.4 &#177; 75 μm，198.8 &#177; 67 μm，单一治疗组CRT 315 &#177; 81 μm，278 &#177; 77 μm (p = 0.041; p = 0.014)，两组差异有显著性意义。治疗后8周联合治疗组视野指数(VFI) 98.0% &#177; 30.8%，单一治疗组VFI 96.7% &#177; 26.8% (p = 0.293)，两组差异没有显著性意义。两组视野平均缺损(MD)，模式标准差(PSD)分别为−1.96 &#177; −0.21 dB，1.77 &#177; 0.30 dB；−2.10 &#177; −0.57 dB，1.53 &#177; 0.27 dB (P = 0.768, P = 0.493)。两组比较差异没有显著性意义。结论：微脉冲视网膜激光光凝联合迈之灵治疗急性CSC与单一视网膜光凝比较能更有效提高BCVA，降低CRT。而两组视野指数，平均缺损，模式标准差比较没有显著性差异，表明微脉冲激光光凝对CSC患者黄斑区视野没有明显影响。
    Objective: To observe the efficacy of subthreshold micro-pulse laser and subthreshold micro-pulse laser combined with Aescuven forte in treatment of acute central serous chorioretinopathy (CSC). Methods: It was a clinical case-control study. 40 patients of acute CSC treated by micro-pulse laser were analyzed from March 2014 to March 2015. 34 cases (42 eyes) with acute CSC were analyzed retrospectively, divided into two groups: mono subthreshold micro-pulse laser treatment (SMLT) and SMLT combined with Aescuven forte. 22 eyes among 34 CSC patients were treated by combined therapy and 20 eyes treated by mono SMLT. The best-correct visual acuity (BCVA), FFA, ICGA, central retinal thickness (CRT), and visual field index of the two groups before and 4, 8 weeks after the treatment were compared. Results: At the 4th and 8th week after treatment: the BCVA of com-bined group was 0.625 &#177; 0.15, 0.77 &#177; 0.17 and the BCVA of mono SMLT group was 0.455 &#177; 0.18, 0.576 &#177; 0.17, there was significant difference between two groups (p = 0.032; 0.027); the central retinal thickness (CRT) of combined group was 208.4 &#177; 75 μm, 198.8 &#177; 67 μm and that of the mono SMLT group was 315 &#177; 81 μm, 278 &#177; 77 μm, there was significant difference between two groups (p = 0.041; 0.014). VFI of combined group was 98.0 &#177; 30.8%, and that of mono therapy was 96.7 &#177; 26.8%. There wasn’t difference between two groups at the 8th week after treatment (p = 0.293). MD and PSD (dB) of two groups were −1.96 &#177; −0.21, 1.77 &#177; 0.30; −2.10 &#177; −0.57, 1.53 &#177; 0.27, respectively. There wasn’t difference between two groups at the 8th week after treatment (p = 0.768, p = 0.493). Conclusion: Combined group could improve BCVA and decrease CFT significantly than mono SMLT group. For the VFI, MD and PSD, there was no difference between the two groups, which indicated that micro-pulse laser had no significant impact on the vision of the macula region. 
  
 
</p></abstract><kwd-group><kwd>脉络膜疾病/药物疗法，激光/治疗应用，植物制剂/治疗应用，迈之灵, Choriodal Diseases/Drug Therapy</kwd><kwd> Laser/Treatment</kwd><kwd> Botanicals/Treatment</kwd><kwd> Aescuven Forte</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>微脉冲激光联合与不联合皂苷类药物治疗急性中心性浆液性视网膜脉络膜病变<sup> </sup></title><p>陈青山<sup>1#</sup>，黄剑虹<sup>2</sup>，马红婕<sup>3</sup>，黄晓生<sup>1</sup>，赵紫媚<sup>1</sup></p><p><sup>1</sup>深圳市眼科医院，深圳市眼科学重点实验室，广东 深圳</p><p><sup>2</sup>北京大学深圳医院眼科，广东 深圳</p><p><sup>3</sup>深圳爱尔眼科医院，广东 深圳</p><disp-formula id="hanspub.19303-formula38"><graphic xlink:href="http://html.hanspub.org/file/5-2230126x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年11月20日；录用日期：2016年12月17日；发布日期：2016年12月20日</p><disp-formula id="hanspub.19303-formula39"><graphic xlink:href="http://html.hanspub.org/file/5-2230126x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：观察微脉冲激光视网膜光凝联合与不联合七叶皂苷素(商品名：迈之灵)治疗急性中心性浆液性视网膜脉络膜病变(Central serous chorioretinopathy, CSC)疗效。方法：临床病例对照研究。选取2014年3月至2015年3月微脉冲激光视网膜光凝治疗的急性CSC患者40例。随机选择单一微脉冲视网膜光凝或与迈之灵联合治疗(以下简称联合治疗)两组，最终完成治疗与随访34例42眼。34例CSC中联合治疗22眼，单一微脉冲激光治疗20眼。比较两组治疗前与治疗后4周，8周最佳矫正视力(BCVA)，FFA及ICGA，黄斑视网膜中心厚度，中心视野的变化。结果：治疗后4周CSC联合治疗组BCVA 0.625 &#177; 0.15，单一治疗组BCVA 0.455 &#177; 0.18 (p = 0.032)，8周联合治疗组BCVA 0.770 &#177; 0.17，单一治疗组BCVA 0.576 &#177; 0.17 (p = 0.027)，两组比较差异均有显著性意义。治疗后4，8周联合治疗组黄斑中心视网膜厚度(CRT)分别为208.4 &#177; 75 μm，198.8 &#177; 67 μm，单一治疗组CRT 315 &#177; 81 μm，278 &#177; 77 μm (p = 0.041; p = 0.014)，两组差异有显著性意义。治疗后8周联合治疗组视野指数(VFI) 98.0% &#177; 30.8%，单一治疗组VFI 96.7% &#177; 26.8% (p = 0.293)，两组差异没有显著性意义。两组视野平均缺损(MD)，模式标准差(PSD)分别为−1.96 &#177; −0.21 dB，1.77 &#177; 0.30 dB；−2.10 &#177; −0.57 dB，1.53 &#177; 0.27 dB (P = 0.768, P = 0.493)。两组比较差异没有显著性意义。结论：微脉冲视网膜激光光凝联合迈之灵治疗急性CSC与单一视网膜光凝比较能更有效提高BCVA，降低CRT。而两组视野指数，平均缺损，模式标准差比较没有显著性差异，表明微脉冲激光光凝对CSC患者黄斑区视野没有明显影响。</p><p>关键词 :脉络膜疾病/药物疗法，激光/治疗应用，植物制剂/治疗应用，迈之灵</p><disp-formula id="hanspub.19303-formula40"><graphic xlink:href="http://html.hanspub.org/file/5-2230126x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC)主要以视力下降、视物变形为主要症状的黄斑疾病，具有自愈倾向。但病程迁延过长或多次复发者黄斑中心凹下长期视网膜神经上皮脱离则可致永久性视力损害，故减少RPE渗漏，促进视网膜下浆液吸收则是治疗的首要目的。激光视网膜光凝可以封闭黄斑中心外RPE渗漏，或刺激RPE功能恢复促进黄斑视网膜神经上皮下浆液吸收 [<xref ref-type="bibr" rid="hanspub.19303-ref1">1</xref>] 。但阈值上的光凝能量对正常的组织会产生一定的损害作用 [<xref ref-type="bibr" rid="hanspub.19303-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.19303-ref2">2</xref>] 。微脉冲激光属阈值下光凝，由于光斑不可见而存在能量不足而造成光凝不足 [<xref ref-type="bibr" rid="hanspub.19303-ref3">3</xref>] 。能否既利用阈值下光凝视网膜损伤较小而又促进黄斑视网膜下浆液吸收完全的治疗？为此我们采用微脉冲光凝联合迈之灵治疗急性CSC，并与单一光凝治疗比较，以期观察联合治疗的疗效优势。</p></sec><sec id="s4"><title>2. 对象和方法</title><p>1) 对象：回顾分析深圳眼科医院，北京大学深圳医院眼科，深圳爱尔眼科医院2014年3月至2015年3月连续急性CSC患者40例。根据EXCEL软件随机选择单一微脉冲视网膜光凝治疗与联合治疗两组各20例，其中6例因自身原因治疗一次后失访，最终完成治疗与随访34例42眼。其中男性29例，女性5例。年龄30~50岁，平均年龄(39.40 &#177; 6.50)岁。34例42眼患者中联合治疗组22眼，单一光凝治疗组20眼。纳入标准：① 病程 ≤ 3个月。② OCT显示黄斑区持续性浆液性视网膜神经上皮脱离伴RPE脱离。③ FFA显示：黄斑区斑点状或弥散性RPE荧光素渗漏，造影晚期神经上皮下及RPE下荧光素积存 [<xref ref-type="bibr" rid="hanspub.19303-ref4">4</xref>] 。④ 排除病程 &gt; 3个月的慢性CSC、点状内层视网膜脉络膜炎(pinctate inner choroidopathy, PIC)，年龄相关性黄斑变性(Age-related macular degeneration, AMD)。</p><p>2) 方法：治疗前进行最佳矫正视力(BCVA)，裂隙灯前置镜，眼底荧光血管造影(FFA)，吲哚青绿脉络膜造影(ICGA)。SD-OCT Humphrey中心视野检查。2组CSC患者均进行577 nm波长的黄光微脉冲激光(法国光太公司)光凝治疗。曝光时间200 ms，光斑150 μm，有效治疗时间(占空比) 5%。采用微脉冲模式下能量滴定确定光凝能量，多点阵列模式，光斑间距0在FFA引导下针对RPE渗漏点进行多点微脉冲阈值下光凝 [<xref ref-type="bibr" rid="hanspub.19303-ref2">2</xref>] 。联合治疗组口服迈之灵(德国礼达药厂生产) 300 mg，一日两次共8周。治疗后4周，8周采用与治疗前相同方法进行BCVA，FFA，ICGA，SD-OCT与Humphrey中心视野检查。对比观察2组治疗前后的结果变化。</p><p>3) 采用spss16.0统计学软件进行统计学分析，计量资料采用均数 &#177; 标准差(X &#177; S)表示，治疗前后自身比较采用配对t检验，两组间比较采用独立样本t检验，p &lt; 0.05为差异有统计学意义。</p></sec><sec id="s5"><title>3. 结果</title><p>治疗后4周急性CSC联合治疗组BCVA 0.625 &#177; 0.15，单一微脉冲治疗组BCVA 0.455 &#177; 0.18 (p = 0.032)，两组差异有显著性意义；治疗后8周联合治疗组BCVA 0.770 &#177; 0.17，单一微脉冲治疗组BCVA 0.576 &#177; 0.17 (p = 0.027)，两组差异有显著性意义(如图1所示)。治疗后4周，8周联合治疗组黄斑中心视网膜厚度(CRT)分别为208.4 &#177; 75 μm，198.8 &#177; 67 μm与单一微脉冲治疗组CRT 315 &#177; 81 μm，278 &#177; 77 μm (p = 0.041; p = 0.014)，两组差异有显著性意义(如图2所示)。治疗后8周联合治疗组视野指数(VFI) 98.0% &#177; 30.8%与单一微脉冲治疗组VFI 96.7% &#177; 26.8% (p = 0.293)，两组差异没有显著性意义。治疗后8周2组视野平均缺损(MD)，模式标准差(PSD)分别为−1.96 &#177; −0.21 dB，1.77 &#177; 0.30 dB；−2.10 &#177; −0.57 dB，1.53 &#177; 0.27 dB (p = 0.768, p = 0.493)。两组比较差异没有显著性意义。</p></sec><sec id="s6"><title>4. 讨论</title><p>CSC普遍认为其发生与患眼的脉络膜血液循环异常有关，脉络膜血管通透性增加导致组织间静水压升高，使与其邻近的RPE遭到破坏，液体通过RPE层渗漏至神经上皮层 [<xref ref-type="bibr" rid="hanspub.19303-ref5">5</xref>] 。传统的连续波激光直接封闭RPE渗漏点被临床证实疗效非常确定 [<xref ref-type="bibr" rid="hanspub.19303-ref6">6</xref>] 。但由于光凝所产生的热量会向与其邻近的视网膜或脉络膜组织传导，导致相应组织损伤，产生RPE疤痕 [<xref ref-type="bibr" rid="hanspub.19303-ref7">7</xref>] 。尤其黄斑中心凹下及中心凹旁的RPE渗漏光凝治疗，</p><p>图1. 联合治疗组与单一微脉冲光凝治疗组BCVA比较</p><p>图2. 联合治疗组与单一微脉冲光凝治疗组CFT比较</p><p>可能严重损伤黄斑视网膜的功能。采用低剂量PDT治疗黄斑中心凹下及中心凹旁的RPE渗漏的急性或慢性CSC能较好促进黄斑视网膜下液吸收 [<xref ref-type="bibr" rid="hanspub.19303-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.19303-ref9">9</xref>] 。但由于PDT光敏剂价格昂贵，治疗过程复杂，限了其在临床中的广泛应用。微脉冲激光是一种短促高频率的重复脉冲激光，因其作用时间短，对邻近的组织损伤极小的特点已成为糖尿病黄斑水肿、视网膜静脉阻塞继发黄斑水肿方法之一 [<xref ref-type="bibr" rid="hanspub.19303-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.19303-ref11">11</xref>] 。目前国内外均有应用810 nm与577 nm波长的激光进行微脉冲模式治疗CSC的文献报道。由于微脉冲激光普遍采用5%占空比的有效工作时限，加上针对不同的CSC患者均要进行能量滴定及阈值下激光反应的特点，因此会有部分患者光凝能量不足产生而治疗效果不佳。宋艳萍等报告一组63只眼急性CSC进行微脉冲治疗，黄斑视网膜下积液完全吸收仅为61.9%，尚有近三分之一的患者一次微脉冲光凝不能痊愈 [<xref ref-type="bibr" rid="hanspub.19303-ref12">12</xref>] 。迈之灵为欧洲马粟的种子提取物，主要药理成分为七叶皂苷 [<xref ref-type="bibr" rid="hanspub.19303-ref13">13</xref>] 。19世纪就用于痔疮的治疗。具有抗渗出，消肿，改善血液微循环，增加静脉血管张力的作用 [<xref ref-type="bibr" rid="hanspub.19303-ref12">12</xref>] CSC发病机制是视网膜内外屏障的破坏，导致脉络膜血管的浆液渗漏至视网膜神经上皮下所致。肖静等 [<xref ref-type="bibr" rid="hanspub.19303-ref14">14</xref>] 研究马粟种子提取物对视网膜水肿的临床观察发现该药可以减少视网膜血管血浆的渗出，从而减轻视网膜神经上皮的水肿。国内有学者单一应用迈之灵或迈之灵联合氩激光光凝治疗视网膜静脉阻塞或缺血型视网膜中央静脉阻塞，治疗后BCVA提高与黄斑视网膜水肿厚度的降低都优于对照组 [<xref ref-type="bibr" rid="hanspub.19303-ref15">15</xref>] 。王俊卿等 [<xref ref-type="bibr" rid="hanspub.19303-ref16">16</xref>] 对近5年14篇有关迈之灵治疗静脉血管性疾病的文献所做的meta分析显示在减少静脉水肿，渗出方面迈之灵优于对照药物。我们的研究结果也表明微脉冲激光阈值下光凝联合迈之灵口服，在提高急性CSC患者BCVA与降低CRT高度方面优于单一微脉冲激光治疗(图3，图4所示)。由于本研究样本例数少，观察时间短。缺乏其他改善视网膜循环药物作为对照，微脉冲激光阈值下光凝联合迈之灵治疗CSC的长期效果还有待进一步研究。</p><p>图3. 微脉冲联合迈之灵治疗8周后黄斑RPE渗漏减轻，OCT显示黄斑视网膜神经上皮下浆液吸收</p><p>图4. 单一微脉冲激光治疗8周后黄斑RPE未减少，OCT显示黄斑视网膜神经上皮下浆液未完全吸收</p></sec><sec id="s7"><title>基金项目</title><p>深圳市科技创新委知识创新计划(JCYJ20150402152130699)。</p></sec><sec id="s8"><title>文章引用</title><p>陈青山,黄剑虹,马红婕,黄晓生,赵紫媚. 微脉冲激光联合与不联合皂苷类药物治疗急性中心性浆液性视网膜脉络膜病变 Micro-Pulse Laser with or without Aescuvenforte for Treatment of Acute Serous Chorioretinopathy[J]. 眼科学, 2016, 05(04): 115-121. http://dx.doi.org/10.12677/HJO.2016.54020</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19303-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gemenetzi, M., Salvo, G.D. and Lotery, A.J. (2010) Central Serous Chorioretinopathy: An Update on Pathogenesis and Treatment. Eye, 24, 1743-1756. https://doi.org/10.1038/eye.2010.130</mixed-citation></ref><ref id="hanspub.19303-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ficker, L., Vafidis, G., While, A., and Leaver, P. (1988) Long-Term Follow-Up of a Prospective Trial of Argon Laser Photocoagulation in the Treatment of Central Serous Retinopathy. British Journal of Ophthalmology, 72, 829-834.  
https://doi.org/10.1136/bjo.72.11.829</mixed-citation></ref><ref id="hanspub.19303-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Scholz, P., Ersoy, L., Boon, C.J., et al. (2015) Subthreshold Micropulse Laser Treatment in Chronic Central Serous Chorioretinopathy. Ophthalmologica, 234, 189-194. https://doi.org/10.1159/000439600</mixed-citation></ref><ref id="hanspub.19303-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">黎晓新, 赵家良, 主译. 浆液性视网膜脱离和色素上皮脱离的病因学. 视网膜[M]. 天津: 天津科技翻译出版公司, 2011: 958-962.</mixed-citation></ref><ref id="hanspub.19303-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">赵明威. 努力探索发病机制, 进一步提升治疗水平: 中心性浆液性视网膜脉络膜病变研究的现实与挑战[J]. 中华眼底病杂志, 2011, 27(4): 305-308.</mixed-citation></ref><ref id="hanspub.19303-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wong, K., Lau, K.P., Chhablani, J., et al. (2016) Central Serous Chorioretinopathy: What We Have Learnt So Far. Acta Ophthalmologica, 94, 321-325. https://doi.org/10.1111/aos.12779</mixed-citation></ref><ref id="hanspub.19303-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李建军, 张风. 中心性浆液性视网膜脉络膜病变治疗进展[J]. 眼科, 2011, 20(4): 230-234.</mixed-citation></ref><ref id="hanspub.19303-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chan, W.M., Lam, D.S., Lai, T.Y., et al. (2003) Choroidal Vascular Remodeling in Central Serous Chorioretinopathy after Indocyanine Green Guided Photodynamic Therapy with Verteporfin: A Novel Treatment at the Primary Level. British Journal of Ophthalmology, 87, 1453-1458. https://doi.org/10.1136/bjo.87.12.1453</mixed-citation></ref><ref id="hanspub.19303-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Reibaldl, M.I., Cardascia, N.I., Longo, A., et al. (2010) Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial. American Journal of Ophthalmology, 149, 307-315. https://doi.org/10.1016/j.ajo.2009.08.026</mixed-citation></ref><ref id="hanspub.19303-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bandello, F., Cunha-Vaz, J., Chong, N.V., et al. (2012) New Approach for the Treatment of Diabetic Macular Edema. Eye, 26, 485-622. https://doi.org/10.1038/eye.2011.337</mixed-citation></ref><ref id="hanspub.19303-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yu, A.K., Merrill, K.D., Truong, S.N., et al. (2013) The Comparative Histologic Effects of Subthreshold 532 – 810 nm Diode Micropulse Laser on Retina. Investigative Ophthalmology &amp; Visual Science, 54, 2216-2224.  
https://doi.org/10.1167/iovs.12-11382</mixed-citation></ref><ref id="hanspub.19303-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">曾苗, 宋艳萍. 微脉冲激光治疗急性中心性浆液性视网膜脉络膜病变疗效观察[J]. 中华眼底病杂志, 2015, 31(3): 230-234.</mixed-citation></ref><ref id="hanspub.19303-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">刘丽娟, 周宏灏. 七叶皂苷的药理作用与临床运用[J]. 现代生物医药进展, 2010, 10(5): 957-960.</mixed-citation></ref><ref id="hanspub.19303-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">肖静, 伍春荣, 夏丽. 马粟种子提取物治疗视网膜水肿的临床观察[J]. 临床和实验药学杂志, 2012, 11(1): 68-69.</mixed-citation></ref><ref id="hanspub.19303-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">宫媛媛, 俞素琴, 王泓. 迈之灵治疗视网膜静脉阻塞[J]. 中国新药与临床杂志, 2005, 24(12): 965-968.</mixed-citation></ref><ref id="hanspub.19303-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王俊卿, 车欣颖. 迈之灵治疗静脉血管疾病临床应用的meta分析[J]. 药学研究, 2013, 32(7): 412-415.</mixed-citation></ref></ref-list></back></article>